Retrophin, Inc. operates as a biopharmaceutical company, which develops pharmaceutical products for the treatment of rare diseases. It focuses on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
